» Drug, Devices, and Supplements

» Physician Accountability

» Consumer Product Safety

» Worker Safety

» Health Care Delivery

» Auto and Truck Safety

» Global Access to Medicines

» Infant Formula Marketing


More Information on Drug Labeling

Food and Drug Administration Petition on Generic Drug Labeling

August 29, 2011, updated April 27, 2015

View the petition (PDF).

View FDA’s response to the petition (PDF).

View the proposed rule (PDF).

View testimony of Allison Zieve, Director of Public Citizen Litigation Group before the Committee on Energy and Commerce, Subcommittee on Health, U.S. House of Representative, March 3, 2014. (Postponed to April 1)

View Public Citizen’s comments on the FDA’s proposed rule to allow generic drug manufacturers to update product labeling with newly discovered risk information, March 13, 2014.

View Public Citizen’s additional comments on the FDA’s proposed generic drug labeling rule and an industry alternative, April 27, 2015.

View Public Citizen press statement about FDA delaying its proposed rule

View press release.

In August 2011, Public Citizen petitioned the Food and Drug Administration (FDA) to revise its regulations to allow generic drug manufacturers to update product labeling to warn patients about newly discovered risks associated with their drugs. Such revisions would cure the illogical disparity between labeling regulations for generic companies and brand-name companies, as brands are permitted to promptly revise drug labeling to provide updated safety information.

The inability of generic companies to revise labeling poses a safety problem because safety issues often arise years after the generic version of a drug has entered the market – sometimes more than a decade later. For example, as Public Citizen explained in a report issued in June 2013, at least 53 drugs approved by the FDA more than 10 years ago have required new black-box warnings over the past five years.

In November 2013, the FDA granted our petition and issued a proposed rule that, when finalized, would establish procedures for generic drug manufacturers to change product labeling to reflect new information in advance of FDA's review of the change. As the FDA explained, the proposed rule will improve the communication of important drug safety information about generic drugs to both prescribers and patients.

Copyright © 2017 Public Citizen. Some rights reserved. Non-commercial use of text and images in which Public Citizen holds the copyright is permitted, with attribution, under the terms and conditions of a Creative Commons License. This Web site is shared by Public Citizen Inc. and Public Citizen Foundation. Learn More about the distinction between these two components of Public Citizen.

Public Citizen, Inc. and Public Citizen Foundation


You can support the fight for greater government and corporate accountability through a donation to either Public Citizen, Inc., or Public Citizen Foundation, Inc.

Public Citizen lobbies Congress and federal agencies to advance Public Citizen’s mission of advancing government and corporate accountability. When you make a contribution to Public Citizen, you become a member of Public Citizen, showing your support and entitling you to benefits such as Public Citizen News. Contributions to Public Citizen are not tax-deductible.

Public Citizen Foundation focuses on research, public education, and litigation in support of our mission. By law, the Foundation can engage in only very limited lobbying. Contributions to Public Citizen Foundation are tax-deductible.